<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30041177</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>07</Month>            <Day>31</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1423-0232</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>94 Suppl 1</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Oncology</Title>                <ISOAbbreviation>Oncology</ISOAbbreviation>            </Journal>            <ArticleTitle>Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?</ArticleTitle>            <Pagination>                <MedlinePgn>29-33</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000489066</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.</AbstractText>                <AbstractText Label="CASE REPORT" NlmCategory="METHODS">We report the case of a 40-year-old woman with MBC and associated lung, bone, liver, and brain metastases, who experienced a time to progression of several months with eribulin after whole-brain radiotherapy (WBRT), 2 lines of chemotherapy, and 1 line of hormonal therapy, maintaining a good toxicity profile.</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Eribulin, in association with local treatment such as WBRT, can be well tolerated and effective in achieving a long progression-free survival and a good control of brain metastases in patients with MBC who have received multiple lines of treatment. The vascular remodeling properties of eribulin, combined with brain radiotherapy, might facilitate the passage of eribulin across the blood brain barrier, improving brain response.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.</AbstractText>                <CopyrightInformation>Â© 2018 S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Catania</LastName>                    <ForeName>Giovanna</ForeName>                    <Initials>G</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Malaguti</LastName>                    <ForeName>Paola</ForeName>                    <Initials>P</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Gasparro</LastName>                    <ForeName>Simona</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Cognetti</LastName>                    <ForeName>Francesco</ForeName>                    <Initials>F</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Vidiri</LastName>                    <ForeName>Antonello</ForeName>                    <Initials>A</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Fabi</LastName>                    <ForeName>Alessandra</ForeName>                    <Initials>A</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D002363">Case Reports</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>24</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Oncology</MedlineTA>            <NlmUniqueID>0135054</NlmUniqueID>            <ISSNLinking>0030-2414</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D005663">Furans</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007659">Ketones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>LR24G6354G</RegistryNumber>                <NameOfSubstance UI="C490954">eribulin</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2002 Jul-Aug;9(4):683-8</RefSource>                <PMID Version="1">12066192</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2014 Mar 20;5(5):320-7</RefSource>                <PMID Version="1">24723974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2015;11(15 Suppl):3-8</RefSource>                <PMID Version="1">26235258</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Surg Neurol Int. 2013 May 02;4(Suppl 4):S236-44</RefSource>                <PMID Version="1">23717795</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Mar 15;7(11):12318-30</RefSource>                <PMID Version="1">26848525</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Mar 12;377(9769):914-23</RefSource>                <PMID Version="1">21376385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Invest. 2006 Jun-Jul;24(4):466-8</RefSource>                <PMID Version="1">16777702</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1507-10</RefSource>                <PMID Version="1">2262373</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Res Notes. 2013 Dec 18;6:541</RefSource>                <PMID Version="1">24350786</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Case Rep Oncol Med. 2012;2012:537183</RefSource>                <PMID Version="1">22953094</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2009 Sep 2;101(17):1174-81</RefSource>                <PMID Version="1">19657108</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2014 Dec;148(3):553-61</RefSource>                <PMID Version="1">25381136</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Exp Metastasis. 2013 Dec;30(8):951-6</RefSource>                <PMID Version="1">23775210</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2013 Jun;18(6):675-84</RefSource>                <PMID Version="1">23740934</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2007 Aug 6;97(3):322-6</RefSource>                <PMID Version="1">17609666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Surg Today. 2016 Jul;46(7):821-6</RefSource>                <PMID Version="1">26467559</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurooncol. 2007 Nov;85(2):223-7</RefSource>                <PMID Version="1">17611719</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2014 Oct;105(10):1334-42</RefSource>                <PMID Version="1">25060424</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Feb 20;33(6):594-601</RefSource>                <PMID Version="1">25605862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2014 Oct;23(5):489-502</RefSource>                <PMID Version="1">25244983</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Brain metastasis</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Eribulin</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30041177</ArticleId>            <ArticleId IdType="pii">000489066</ArticleId>            <ArticleId IdType="doi">10.1159/000489066</ArticleId>            <ArticleId IdType="pmc">PMC6193747</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>